Novartis receives FDA approval for BEOVUŽ, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

Tuesday, October 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

- In two head-to-head clinical trials, patients on BEOVU (brolucizumab-dbll) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients[1,2]

Central

North America

Samir Shah

+41 61 324 7944

Sloan Simpson

+1 862 778 5052

Pierre-Michel Bringer

+41 61 324 1065

Cory Twining

+1 212 778 3258

Thomas Hungerbuehler

+41 61 324 8425

Isabella Zinck

+41 61 324 7188



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store